The Fisher exact test showed significant relationship between CTNNB1 mutation status and PD-L1 tumor proportion score (TPS) when categorized as <1%, 1%-49%, and ≥50% (χ2(2) = 13.805; P = .001), confirming the observation that CTNNB1-mutated patients by mean had a lower PD-L1 TPS. Here, CTNNB1 is linked to neoplasm.